ReviewArthritis research & therapy2005
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.
Review in Arthritis research & therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 378 citations in OpenAlex.
- B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls.PloS one · 2013Trial
- Immunosenescence and Bone Homeostasis: From Mechanisms of Homeostasis Disruption to Therapeutic Opportunities in Age-Related Skeletal Disorders.International journal of molecular sciences · 2026Review
- Narrative review on the development of multi-target pharmacological agents for the management of rheumatoid arthritis.Inflammopharmacology · 2026Review
- Systemic neutrophil activation and N-formyl methionine-formyl peptide receptor-1 signaling define inflammatory endotypes in rheumatoid arthritis-associated lung involvement.Journal of internal medicine · 2025Article
- Article
- IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3.Rheumatology (Oxford, England) · 2023Article
- Article
- The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism.Frontiers in endocrinology · 2022Review
- Angiotensin ATFrontiers in immunology · 2022Article
- 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development.Immunologic research · 2021Article
- Article
- Potential role of myeloid-derived suppressor cells in transition from reaction to repair phase of bone healing process.International journal of medical sciences · 2021Article
- Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.Nature reviews. Rheumatology · 2021Review
- Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases.Journal of translational autoimmunity · 2021Article
- Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.ImmunoTargets and therapy · 2021Review
- Hydroxychloroquine in rheumatic autoimmune disorders and beyond.EMBO molecular medicine · 2020Review
- Interleukin-17 suppresses grass carp reovirus infection inAquaculture (Amsterdam, Netherlands) · 2020Article
- Interleukin-17A Facilitates Chikungunya Virus Infection by Inhibiting IFN-α2 Expression.Frontiers in immunology · 2020Article
- Andrographolide Ameliorates Rheumatoid Arthritis by Regulating the Apoptosis-NETosis Balance of Neutrophils.International journal of molecular sciences · 2019Article
- A single administration of human adipose tissue-derived mesenchymal stromal cells (MSC) induces durable and sustained long-term regulation of inflammatory response in experimental colitis.Clinical and experimental immunology · 2019Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis (RA) synovial membranes. High levels have been detected in the synovial fluid of patients with RA. The trigger for IL-17 is not fully identified; however, IL-23 promotes the production of IL-17 and a strong correlation between IL-15 and IL-17 levels in synovial fluid has been observed. IL-17 is a potent inducer of various cytokines such as tumor necrosis factor (TNF)-alpha, IL-1, and receptor activator of NF-kappaB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-alpha in inducing cytokine expression and joint damage have been shown in vitro and in vivo. This review describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant when T cells are a major element of the arthritis process. Moreover, IL-17 has the capacity to induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17 cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in situations in which elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.